Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
9 participants
INTERVENTIONAL
2014-01-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
NCT02383043
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
NCT02444208
Cocaethylene as a Treatment for Cocaine Dependence - 1
NCT00124696
Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
NCT01929343
Improving Learning-based Treatment of Cocaine Dependence With Medication
NCT01526538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Value Alternative Reinforcer
A low value reinforcer will be made available as an alternative to cocaine and placebo.
Cocaine
Three active doses of cocaine will be made available for self-administration during experimental sessions.
Placebo
Placebo cocaine will be made available for self-administration during experimental sessions.
Medium Value Reinforcer
A medium value reinforcer will be made available as an alternative to cocaine and placebo.
Cocaine
Three active doses of cocaine will be made available for self-administration during experimental sessions.
Placebo
Placebo cocaine will be made available for self-administration during experimental sessions.
High Value Reinforcer
A high value reinforcer will be made available as an alternative to cocaine and placebo.
Cocaine
Three active doses of cocaine will be made available for self-administration during experimental sessions.
Placebo
Placebo cocaine will be made available for self-administration during experimental sessions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocaine
Three active doses of cocaine will be made available for self-administration during experimental sessions.
Placebo
Placebo cocaine will be made available for self-administration during experimental sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Joshua A. Lile, Ph.D.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joshua A. Lile, Ph.D.
Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joshua A Lile, Ph.D
Role: PRINCIPAL_INVESTIGATOR
University of Kentucky
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory of Human Behavioral Pharmacology
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.